
Non-Sponsored Content
Pertuzumab plus trastuzumab and chemotherapy FDA approved as adjuvant treatment of HER2-positive breast cancer with high recurrence score
By: News Feed | Last updated: 20th December 2017 | In: US FDA Onc\Haem Approvals
Article Keywords
FDA, Genentech, HER2, Perjeta, pertuzumab, Roche, trastuzumab
On 20 December 2017, the FDA granted regular approval to pertuzumab (Perjeta®, Roche/Genentech) for use with trastuzumab and chemotherapy as adjuvant treatment of patients with HER2-positive early breast cancer and a high recurrence risk.
Disclaimer
This article is not medical advice. Patients should seek personal assessment by a licenced specialist. Physicians are recommended to read the full publication(s) as cited in the article before making medical decisions. This article does not supersede nor replace the published article(s).
© Copyright 2018 MediPaper Medical Communications Ltd.
YOU MAY ALSO LIKE




































































Venetoclax plus azacitidine, decitabine, or low-dose cytarabine FDA approved in elderly AML patients












































































































© Copyright 2018 MediPaper Medical Communications Ltd.
Leave a Reply
Want to join the discussion?Feel free to contribute!